Table 4.
Three-Year Survival Estimates: Patient and Clinical Characteristics
| Characteristic | No. of Patients | Relapse-Free Survival |
Overall Survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of Events | 3-Year Estimate | 95% CI | P | No. of Events | 3-Year Estimate | 95% CI | P | ||
| Beta blocker | |||||||||
| No | 1,311 | 387 | 0.77 | 0.74 to 0.79 | 335 | 0.85 | 0.83 to 0.87 | ||
| Yes | 102 | 17 | 0.87 | 0.78 to 0.92 | .008 | 18 | 0.91 | 0.83 to 0.95 | .09 |
| Age, years | |||||||||
| < 50 | 722 | 229 | 0.75 | 0.71 to 0.78 | 179 | 0.85 | 0.82 to 0.88 | ||
| ≥ 50 | 691 | 175 | 0.81 | 0.77 to 0.83 | .003 | 174 | 0.86 | 0.83 to 0.88 | .75 |
| Race | |||||||||
| Non-black | 1,211 | 320 | 0.79 | 0.77 to 0.82 | 271 | 0.87 | 0.85 to 0.89 | ||
| Black | 202 | 84 | 0.67 | 0.6 to 0.73 | < .001 | 82 | 0.77 | 0.71 to 0.83 | < .001 |
| Body mass index | |||||||||
| Normal/underweight | 468 | 128 | 0.8 | 0.76 to 0.84 | 102 | 0.88 | 0.85 to 0.91 | ||
| Overweight | 441 | 117 | 0.8 | 0.75 to 0.83 | 100 | 0.87 | 0.83 to 0.89 | ||
| Obese | 460 | 145 | 0.73 | 0.69 to 0.77 | .07 | 138 | 0.82 | 0.78 to 0.85 | .001 |
| Clinical stage | |||||||||
| I/II | 823 | 182 | 0.85 | 0.82 to 0.87 | 151 | 0.91 | 0.89 to 0.93 | ||
| III | 585 | 218 | 0.68 | 0.64 to 0.71 | < .001 | 197 | 0.78 | 0.74 to 0.81 | < .001 |
| Nuclear grade | |||||||||
| I/II | 500 | 104 | 0.86 | 0.83 to 0.89 | 82 | 0.95 | 0.92 to 0.96 | ||
| III | 873 | 287 | 0.73 | 0.7 to 0.76 | < .001 | 257 | 0.8 | 0.77 to 0.83 | < .001 |
| LVI | |||||||||
| Negative | 935 | 212 | 0.83 | 0.8 to 0.85 | 182 | 0.88 | 0.86 to 0.9 | ||
| Positive | 428 | 172 | 0.67 | 0.63 to 0.72 | < .001 | 149 | 0.81 | 0.77 to 0.84 | < .001 |
| Hormone receptor status | |||||||||
| Negative | 505 | 187 | 0.66 | 0.62 to 0.71 | 172 | 0.74 | 0.7 to 0.78 | ||
| Positive | 908 | 217 | 0.84 | 0.81 to 0.86 | < .001 | 181 | 0.92 | 0.9 to 0.94 | < .001 |
| HER2 status | |||||||||
| Negative | 1,145 | 308 | 0.78 | 0.76 to 0.81 | 279 | 0.86 | 0.83 to 0.88 | ||
| Positive | 251 | 91 | 0.74 | 0.68 to 0.79 | .02 | 70 | 0.84 | 0.78 to 0.88 | .99 |
| Triple-negative tumor | |||||||||
| No | 1,019 | 263 | 0.82 | 0.79 to 0.84 | 216 | 0.9 | 0.88 to 0.92 | ||
| Yes | 377 | 136 | 0.66 | 0.61 to 0.71 | < .001 | 133 | 0.72 | 0.67 to 0.76 | < .001 |
| Diabetes | |||||||||
| No | 1,336 | 380 | 0.78 | 0.76 to 0.8 | 324 | 0.86 | 0.84 to 0.88 | ||
| Yes | 77 | 24 | 0.72 | 0.6 to 0.81 | .42 | 29 | 0.76 | 0.64 to 0.84 | .002 |
| Hypertension | |||||||||
| No | 1,058 | 307 | 0.77 | 0.75 to 0.8 | 258 | 0.85 | 0.83 to 0.87 | ||
| Yes | 355 | 97 | 0.79 | 0.74 to 0.83 | .37 | 95 | 0.86 | 0.82 to 0.89 | .61 |
| ACEIs/ARBs | |||||||||
| No | 1,273 | 371 | 0.77 | 0.75 to 0.79 | 316 | 0.86 | 0.84 to 0.88 | ||
| Yes | 140 | 33 | 0.81 | 0.74 to 0.87 | .21 | 37 | 0.83 | 0.76 to 0.88 | .58 |
Abbreviations: LVI, lymphovascular invasion; HER2, human epidermal growth factor receptor 2; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.